CTSO Nasdaq Surgical & Medical Instruments & Apparatus Financials FY2016βFY2025
Cytosorbents Corp had $37.1M of revenue in fiscal 2025, up 4.1% on the year before. Over five years, revenue changed β2.0% a year on average.
Last close Β· Oct 23, 2026
$5.27
12.3%Hi! I read Cytosorbents Corpβs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+4.1%
Only a little. Sales grew 4.1% last year.
Does it make a profit?
β22.1%
No. It lost money last year.
Does profit turn into cash?
β33.8%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 9
Weak. It passes 3 of 9 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Cytosorbents Corp did it, and the next one. Share prices often move a lot on those days.
Next results
November 12, 2026
Thursday Β· in 17 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 6, 2026 | Q2 '26 | After the market closes | 8-K β |
| May 13, 2026 | Q1 '26 | After the market closes | 8-K β |
| Mar 25, 2026 | Q4 '25 | After the market closes | 8-K β |
| Nov 13, 2025 | Q3 '25 | After the market closes | 8-K β |
| Aug 7, 2025 | Q2 '25 | After the market closes | 10-Q β |
| May 14, 2025 | Q1 '25 | After the market closes | 8-K β |
| Jan 3, 2025 | Q4 '24 | After the market closes | 8-K β |
| Oct 1, 2024 | Q3 '24 | Before the market opens | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Cytosorbents Corp had $37.1M of revenue in fiscal 2025, up 4.1% on the year before. Over five years, revenue changed β2.0% a year on average. Its operating margin was β39.8%, up 6.4Β pts: of every 100 in sales, about β40 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Cytosorbents Corp lost $8.2M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$12.5M in fiscal 2025, β33.8% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
KIRA Β· Cytosorbents Corp owes $10.4M more than it holds in cash.
Cash, debt and the ratios that show how comfortably Cytosorbents Corp can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $52.1M | $22.1M | $14.1M | $3.3M | $6.2M |
| Debt incl. finance leases | β | $5.0M | $5.0M | $14.0M | $16.7M |
| Debt / equity | β | 0.1x | 0.2x | 1.3x | 2.8x |
| Current ratio | 4.7x | 3.5x | 1.8x | 2.2x | 2.1x |
| Quick ratio | 4.3x | 3.1x | 1.6x | 1.9x | 1.6x |
| Total assets | $89.5M | $63.2M | $53.0M | $47.4M | $44.2M |
| Total liabilities | $26.9M | $27.9M | $29.5M | $36.3M | $38.3M |
| Shareholders' equity | $62.6M | $35.4M | $23.5M | $11.1M | $5.9M |
| Net debt (β = net cash) | β | β$17.1M | β$9.1M | $10.7M | $10.4M |
KIRA Β· Its return on capital was β71.4%: every 100 invested in the business earned about β71 in a year.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Cytosorbents Corp passes 3 of 9 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 5 / 9 | 5 / 9 | 3 / 9 | 5 / 9 | 3 / 8 | 2 / 8 | 3 / 9 | 4 / 9 | 3 / 9 |
| Accruals ratio | β51.9% | β11.8% | β21.9% | β8.1% | β3.8% | β11.8% | β6.0% | β13.1% | β12.5% | 9.1% |
| Altman Z'' | β53.66 | β19.06 | β14.10 | β24.36 | 5.12 | β3.61 | β12.62 | β19.25 | β21.30 | β23.50 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $9.5M | $15.2M | $22.5M | $24.9M | $41.0M | $43.2M | $34.7M | $31.1M | $35.6M | $37.1M |
| Gross profit | $5.6M | $9.6M | $15.0M | $17.6M | $30.0M | $32.1M | $20.7M | $22.0M | $24.9M | $26.5M |
| Research and development | $4.1M | $3.2M | $7.7M | $12.1M | $8.8M | $16.4M | $15.1M | $15.7M | β | β |
| Operating income | β$11.5M | β$9.8M | β$15.6M | β$19.0M | β$10.4M | β$22.7M | β$31.5M | β$31.9M | β$16.5M | β$14.7M |
| Pretax income | β$12.1M | β$9.1M | β$17.8M | β$20.4M | β$9.0M | β$25.3M | β$33.9M | β$30.1M | β$22.4M | β$8.6M |
| Income tax | β$0.3M | β$0.7M | β$0.6M | β$1.1M | β$1.1M | β$0.7M | β$1.1M | β$0.8M | β$1.7M | β$0.4M |
| Net income | β$11.8M | β$8.5M | β$17.2M | β$19.3M | β$7.8M | β$24.6M | β$32.8M | β$29.2M | β$20.7M | β$8.2M |
| Net income to common | β$11.8M | β$8.8M | β$17.2M | β$19.3M | β$7.8M | β$24.6M | β$32.8M | β$29.2M | β$20.7M | β$8.2M |
| Diluted EPS | β$0.46 | β$0.32 | β$0.56 | β$0.60 | β$0.20 | β$0.57 | β$0.75 | β$0.65 | β$0.38 | β$0.13 |
| Diluted shares | 0.03B | 0.03B | 0.03B | 0.03B | 0.04B | 0.04B | 0.04B | 0.04B | 0.05B | 0.06B |
| Cash flow | ||||||||||
| Cash from operations | β$6.7M | β$6.5M | β$10.8M | β$16.8M | β$5.6M | β$14.0M | β$28.2M | β$21.7M | β$14.4M | β$12.4M |
| Capital expenditure | $0.1M | $1.0M | $0.7M | $0.7M | $0.7M | $3.6M | $6.1M | $0.5M | $0.3M | $0.2M |
| Free cash flow | β$6.9M | β$7.5M | β$11.5M | β$17.5M | β$6.3M | β$17.6M | β$34.3M | β$22.2M | β$14.7M | β$12.5M |
| Depreciation and amortization | $0.2M | $0.2M | $0.4M | $0.6M | $0.7M | $0.7M | $0.9M | $1.5M | $1.3M | $1.2M |
| Stock-based compensation | $2.8M | $3.3M | $4.4M | $1.7M | $3.5M | $4.0M | $3.4M | $4.2M | $3.8M | $2.8M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $5.2M | $17.3M | $22.4M | $12.2M | $71.4M | $52.1M | $22.1M | $14.1M | $3.3M | $6.2M |
| Total debt | $4.9M | $10.0M | $9.9M | $15.1M | $0.0M | β | $5.0M | $5.0M | $14.0M | $16.7M |
| Current assets | $7.8M | $20.7M | $28.3M | $20.9M | $82.5M | $64.3M | $33.8M | $25.4M | $21.6M | $20.6M |
| Current liabilities | $4.3M | $7.8M | $6.9M | $9.9M | $10.2M | $13.7M | $9.7M | $14.0M | $9.8M | $9.7M |
| Inventory | $0.8M | $0.8M | $0.8M | $2.1M | $2.7M | $4.8M | $3.5M | $3.4M | $2.7M | $5.3M |
| Property and equipment, net | $0.6M | $1.4M | $1.7M | $1.9M | $2.1M | $5.2M | $10.7M | $10.1M | $9.0M | $7.8M |
| Intangible assets | β | $1.8M | $2.6M | $3.4M | $4.2M | $4.7M | $4.4M | $3.9M | $3.7M | $3.2M |
| Total assets | $9.7M | $24.1M | $34.2M | $27.4M | $90.0M | $89.5M | $63.2M | $53.0M | $47.4M | $44.2M |
| Total liabilities | $8.4M | $13.8M | $17.3M | $24.0M | $10.7M | $26.9M | $27.9M | $29.5M | $36.3M | $38.3M |
| Preferred stock | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | β | β | β | β |
| Shareholders' equity | $1.3M | $10.3M | $16.9M | $3.4M | $79.2M | $62.6M | $35.4M | $23.5M | $11.1M | $5.9M |
| Margins | ||||||||||
| Gross margin | 58.5% | 63.6% | 66.7% | 70.5% | 73.0% | 74.4% | 59.8% | 70.6% | 69.9% | 71.5% |
| Operating margin | β120.6% | β65.0% | β69.3% | β76.1% | β25.3% | β52.7% | β90.9% | β102.8% | β46.2% | β39.8% |
| EBITDA margin | β118.9% | β63.5% | β67.5% | β73.7% | β23.7% | β51.0% | β88.3% | β98.1% | β42.5% | β36.5% |
| Net margin | β123.5% | β55.8% | β76.5% | β77.2% | β19.1% | β56.9% | β94.6% | β94.1% | β58.2% | β22.1% |
| FCF margin | β72.1% | β49.2% | β51.2% | β70.0% | β15.4% | β40.9% | β98.9% | β71.4% | β41.3% | β33.8% |
| Returns | ||||||||||
| Return on capital | β904.3% | β265.1% | β273.2% | β240.3% | β105.1% | β | β136.6% | β175.4% | β59.6% | β71.4% |
| Return on capital employed | β212.2% | β60.6% | β57.1% | β108.8% | β13.0% | β30.0% | β58.9% | β82.1% | β43.8% | β42.8% |
| Return on equity | β879.5% | β145.9% | β126.6% | β189.3% | β19.0% | β34.6% | β67.0% | β99.4% | β119.8% | β96.4% |
| Return on assets | β121.4% | β50.1% | β59.0% | β62.6% | β13.4% | β27.4% | β43.0% | β50.3% | β41.3% | β17.9% |
| Return on tangible equity | β879.5% | β104.4% | β120.3% | β34,038.2% | β10.5% | β42.4% | β105.9% | β149.4% | β280.5% | β306.2% |
| Growth | ||||||||||
| Revenue growth | β | 59.0% | 48.5% | 10.9% | 64.4% | 5.3% | β19.6% | β10.4% | 14.5% | 4.1% |
| Share count change | β | 8.6% | 11.2% | 5.0% | 20.3% | 11.7% | 0.5% | 2.5% | 21.9% | 14.3% |
| Financial health | ||||||||||
| Debt / equity | 3.7x | 1.0x | 0.6x | 4.4x | 0.0x | β | 0.1x | 0.2x | 1.3x | 2.8x |
| Current ratio | 1.8x | 2.6x | 4.1x | 2.1x | 8.1x | 4.7x | 3.5x | 1.8x | 2.2x | 2.1x |
| Quick ratio | 1.6x | 2.5x | 4.0x | 1.9x | 7.9x | 4.3x | 3.1x | 1.6x | 1.9x | 1.6x |
| Capital allocation | ||||||||||
| Capex / revenue | 1.5% | 6.5% | 3.0% | 2.8% | 1.7% | 8.4% | 17.5% | 1.7% | 0.8% | 0.4% |
| Stock comp / revenue | 28.9% | 21.9% | 19.7% | 6.7% | 8.6% | 9.3% | 9.9% | 13.4% | 10.6% | 7.5% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 5.0 | 5.0 | 3.0 | 5.0 | 3.0 | 2.0 | 3.0 | 4.0 | 3.0 |
| Altman Z'' | β53.7 | β19.1 | β14.1 | β24.4 | 5.1 | β3.6 | β12.6 | β19.2 | β21.3 | β23.5 |
| Accruals ratio | β51.9% | β11.8% | β21.9% | β8.1% | β3.8% | β11.8% | β6.0% | β13.1% | β12.5% | 9.1% |
Source: SEC EDGAR XBRL filings (CIK 0001175151). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
